Mark Joseph Enyedy net worth and biography

Mark Enyedy Biography and Net Worth

President, CEO & Director of ImmunoGen

Mr. Enyedy joined ImmunoGen in 2016 as President and CEO, bringing over twenty-five years of combined general management, business development and legal experience in the biotechnology industry. He joined ImmunoGen from Shire plc, where he served as Executive Vice President and Head of Corporate Development, leading the company’s Strategy, M&A, and Corporate Planning functions and providing commercial oversight for the company’s pre-Phase 3 portfolio. Previously, Mr. Enyedy served as CEO of Proteostasis Therapeutics, Inc., following 15 years at Genzyme Corporation in diverse roles, most recently as President of the Transplant, Oncology, and Multiple Sclerosis divisions. Before joining Genzyme, Mr. Enyedy was an associate with the Boston law firm Palmer & Dodge. He holds a J.D. from Harvard Law School and a B.S. from Northeastern University. Mr. Enyedy also serves on the Board of Directors of LogicBio Therapeutics, Inc., Ergomed plc, The American Cancer Society of Eastern New England, and the Biotechnology Innovation Organization. He previously served on the Board of Directors of Akebia Therapeutics, Inc., Fate Therapeutics, Inc., and Keryx Biopharmaceuticals, Inc.

How old is Mark Joseph Enyedy?: Mr. Enyedy is currently 60 years old. There are 4 older executives and no younger executives at ImmunoGen. The oldest executive at ImmunoGen is Dr. Theresa G. Wingrove, Senior Vice President of Regulatory Affairs & Quality, who is 66 years old. Learn More on Mark Joseph Enyedy's age.
How do I contact Mark Joseph Enyedy?: The corporate mailing address for Mr. Enyedy and other ImmunoGen executives is 830 WINTER ST, WALTHAM MA, 02451. ImmunoGen can also be reached via phone at (781) 895-0600 and via email at courtney.okonek@immunogen.com. Learn More on Mark Joseph Enyedy's contact information.
Has Mark Joseph Enyedy been buying or selling shares of ImmunoGen?: Mark Joseph Enyedy has not been actively trading shares of ImmunoGen within the last three months. Learn More on Mark Joseph Enyedy's trading history.
Who are ImmunoGen's active insiders?: ImmunoGen's insider roster includes Susan Altschuller (Sr. VP & CFO ), Stacy Coen (SVP), Mark Enyedy (President, CEO & Director), Mark Enyedy (CEO), Renee Lentini (Insider), Kristine Peterson (Director), and Theresa Wingrove (SVP). Learn More on ImmunoGen's active insiders.

Mark Joseph Enyedy Insider Trading History at ImmunoGen

Mark Joseph Enyedy Buying and Selling Activity at ImmunoGen

ImmunoGen Company Overview

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.

Today's Range

Now: N/A

50 Day Range

MA: $31.23

$31.23

2 Week Range

Now: N/A

Volume

40 shs

Average Volume

8,778,325 shs

Market Capitalization

$8.32 billion

P/E Ratio

N/A

Dividend Yield